Phase III Clinical Trial For ADENTRI(R) For Acute Decompensated Heart Failure Patients With Renal Insufficiency

�Biogen Idec (Nasdaq: BIIB) announced the initiation of a Phase III clinical trial of intravenous (IV) ADENTRI� (BG9928), an adenosine A1 sense organ antagonist, for acute decompensated heart failure (ADHF) patients with nephritic insufficiency. The trial will evaluate ADENTRI, which is being developed under a licensing agreement with CV Therapeutics (Nasdaq: CVTX), or placebo in addition to standard of care in approximately 900 patients in 21 countries globally, including the United States.


The TRIDENT-1 (TReatment with Intravenous BG9928 for patients with acutely DEcompensated heart failure and reNal insufficiency Trial) study is a Phase III randomised, multi-center, double blind, placebo-controlled, parallel-group study to assess the efficacy and safety of IV ADENTRI dosed up to five-spot days on body weight in ADHF patients with impaired nephritic function. Body weight is a bill of liquid accumulation, which is considered an important cause of symptoms experienced by pump failure patients.


"In previous clinical studies, ADENTRI has exhibited the potential to optimize runny management without harmful personal effects on renal function. Heart failure patients with renal insufficiency ar at danger for poor clinical outcomes and ar among the most difficult to handle, as presently available therapies negatively impingement renal part," said lead investigator William Abraham, M.D., Professor of Internal Medicine and Director of the Division of Cardiovascular Medicine, The Ohio State University Medical Center.


"We ar excited to see ADENTRI enter into Phase III studies as one of Biogen Idec's lead cardiorespiratory programs," said Barry Ticho, M.D., Ph.D., Vice President, Cardiopulmonary and Emerging Therapies, Biogen Idec. "Following lixivaptan, ADENTRI simon Marks the secondment novel compound in Biogen Idec's cardiorespiratory franchise that is in Phase III clinical trials for heart failure patients. We appear forward to advancing this and our other programs in the future."


According to the American Heart Association, spunk failure is the most common causal agent of hospitalizations in the U.S. Studies have shown that more than 60% of patients hospitalized with heart bankruptcy have renal insufficiency, which is an important sovereign determinant of survival and hospitalization in this clinical setting. The effect of renal insufficiency on sharp decompensated heart failure patients is significant as these patients tend to keep back fluid, which causes stress on both the cardiovascular and nephritic systems.

About Biogen Idec


Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis and rheumy arthritis. For product labeling, press releases and extra information near the company, please visit http://www.biogenidec.com.

Biogen Idec Safe Harbor


This press release contains advanced statements regarding ADENTRI. These statements ar based on Biogen Idec's current beliefs and expectations. The commercial potential of ADENTRI is subject to a number of risks and uncertainties, including the risk of meeting the end points in clinical trials, early unexpected delays or hurdle race, and the uncertainty of obtaining regulative approval. Drug development and commercialization involves a high gear degree of risk.


For more elaborate information on the risks and uncertainties associated with Biogen Idec's drug development and other activities, see Item 1A "Risk Factors" in Biogen Idec's most recent Form 10-Q filing with the Securities and Exchange Commission. These fore looking statements speak only as of the date of this press acquittance, and we assume no obligation to update any forward-looking statements, whether as a result of newfangled information, future events or otherwise.

Biogen Idec Safe Harbor


More info

• New test detects arthritis early
• Dr. Drew Denies Ties to Rehab Deaths
• Test your sexual potential
• Infections may cause premature births
• The types of hair loss and treatment of hair loss

Ex-Oasis member hits the road

Former Oasis guitarist Paul 'Bonehead' Arthurs is go under to promontory out on tour alongside Scottish singer-songwriter Pete MacLeod this October.


The duo testament appear on stage together at the following venues:



Mansfield The Mill (31 October)

London Brixton Jamm (November 1)

Dublin Whelans (3)

Limerick TBC (4)

Limerick Dolans (5)

Rahan The Thatch (6)

Mullingar Stables (7)

Carlisle Thyme And Spirit (8)

Accrington The Attic (14)

Oswestry The Ironworks (15)

Glasgow Pivo Pivo (22)



Since leaving Oasis in 1999, Bonehead has played in bands aboard The Smiths' Andy Rourke and Mike Joyce. He also presents a radio show for BBC Radio Manchester alongside Terry Christian.


To check the availability of Bonehead tickets and come all the latest listings, go to NME.COM/GIGS now, or holler 0871 230 1094.



More info

• Sinner
• American Idol - Nasty Nigel To Leave American Idol
• Trancenation
• Live: Jordin Sparks and Jesse McCartney
• Sam Brown

Graham Bonnet

   
Artist: Graham Bonnet

   Genre(s): 
Rock
   Rock: Hard-Rock
   

---

Discography:


   
 Day I Went Mad

   Year: 2003   
Tracks: 11


   
 The Day I Went Mad

   Year: 1999   
Tracks: 11


   
 Underground

   Year: 1998   
Tracks: 10


   
 Here Comes The Night

   Year: 1993   
Tracks: 12


   
 Line-Up

   Year: 1981   
Tracks: 11


   
 No Bad Habits

   Year: 1978   
Tracks: 11


   
 Graham Bonnet

   Year: 1977   
Tracks: 10

---

In the eighties, tough stone and sonorous metal were all more or less the manner you looked. If you didn't have long hair and dress up in studs, spikes, leather, or spandex, you stuck out like a sore thumb. Singer Graham Bonnet -- wHO sported a take fear that was equal parts James Dean and Miami Vice-era Don Johnson -- was a prize example of this, disdain fronting (albeit in short) such far-famed acts as Rainbow, the Michael Schenker Group, and Alcatrazz. Born December 23, 1947, in Skegness, Lincolnshire, England, Bonnet had his first taste of succeeder in the music biz in the late '60s, when he scored a off with his isthmus, the Marbles -- "Only One Woman." Bonnet purportedly worn prohibited nigh of the '70s doing commercial jingles, ahead issue a self-titled solo debut in 1977, which became a hit in Australia referable to a cover of Bob Dylan's "It's All Over Now, Baby Blue," and leveling some other cover hit a twelvemonth subsequently with the Bee Gees' "Warm Ride." Just in front the close of the decennium, Bonnet was elect to supplant Ronnie James Dio in Rainbow, which saw the chemical group transform into a more melodious and radio-friendly work with 1980's Down to Earth.


Just Bonnet's land tenure with Rainbow was passing, as he then returned to a solo career, marking a U.K. hit single with "Night Games" cancelled of 1981's Line Up. Up next was some other brief association, with the Michael Schenker Group, which also lasted for a single record album -- 1982's Rape Attack. A year later, Bonnet co-formed an all new band, Alcatrazz, which featured two of the biggest careen guitar heroes of the '80s -- Yngwie Malmsteen (on 1984's No Parole from Rock 'n' Roll and Live Sentence) and Steve Vai (on 1985's Perturbing the Peace). However, after a third studio album, 1986's Unsafe Games, Alcatrazz were kaput. Subsequently, Bonnet has appeared on albums by others -- including Pretty Maids, Impellitteri, and Eddie Hardin -- and has also periodically issued further solo sets (1991's Hither Comes the Night, 1997's Underground, and 1999's The Day I Went Mad).